An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Malignant Solid Tumour|Ovarian Cancer|Triple Negative Breast Cancer|Advanced Melanoma|B-cell Malignancy, Low-grade
Interventions: DRUG: E7449 alone|DRUG: E7449 plus TMZ|DRUG: E7449 plus carboplatin and paclitaxel
Sponsor: Eisai Limited